Tarceva (OSI-774 or erlotinib) : OSI Pharmaceuticals/Genentech : EGFR inhibitor

Tarceva (Erlotinib) Extends Survival in Advanced Lung Cancer (National Cancer Institute)
Discusses the results of a controlled Phase III study of Tarceva (erlotinib), a targeted drug that inhibits the epidermal growth factor receptor (EGFR). The study showed improved survival in previously treated patients with NSCLC - patients receiving Tarceva lived longer than those in the placebo arm of the study. The trial also demonstrated that Tarceva improved: 1) time to symptomatic deterioration; 2) progression-free survival and response rate. [6/04]

Tarceva & Lung Cancer - Recent MEDLINE Abstracts

Tarceva - Clinical Trials (ClinicalTrials.gov)